The outbreak of COVID-19 has become a global crisis, and brought severe disruptions to
societies and economies. Until now, effective therapeutics against COVID-19 are in high …

Background Little is known about the real-world effectiveness of oral antivirals against the
SARS-CoV-2 omicron (B. 1.1. 529) variant. We aimed to assess the clinical effectiveness of …

Background Sphingosine-one phosphate receptor (S1PR) modulation inhibits S1PR1-
mediated lymphocyte migration, lesion formation and positively-impacts on active multiple …

Background. Several drugs which are easy to administer in outpatient settings have been
authorized and endorsed for high-risk COVID-19 patients with mild–moderate disease to …

Objectives Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has become
established in the human population, making the need to develop safe and effective …

ABSTRACT Introduction On 31 July 2023, the United States Department of Health and
Human Services announced the formation of the Office of Long COVID Research and …

Autoimmune systemic diseases (ASD) show impaired immunogenicity to COVID-19
vaccines. Our prospective observational multicenter study aimed at evaluating the …

In 1918 many countries, but not Spain, were fighting World War I. Spanish press could report
about the diffusion and severity of a new infection without censorship for the first-time, so that …

Abstract On December 22, 2021, the United States Food and Drug Administration approved
the first main protease inhibitor, ie, oral antiviral nirmatrelvir (PF-07321332)/ritonavir …

The small-molecule antiviral drug ensitrelvir targets the 3C-like protease of severe acute
respiratory syndrome coronavirus 2 (SARS-CoV-2). This study evaluated its inhibitory effect …